USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOPAL, INC
Address:
80 WEBSTER ST
WORCESTER, MA
Phone:
N/A
URL:
N/A
EIN:
104339054
DUNS:
9796223
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $446,453.00 3
SBIR Phase II $1,711,036.00 2

Award List:

Glomerular filtration rate test

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$748,036.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Kidney disease in the United States has been described as an epidemic. More than 20 million patients have chronic kidney disease (CKD) and these numbers are increasing annually. As a result, the number of patients with end-stage renal disease (ESRD) is expected… More

Inulin immunoassay for kidney function

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$97,905.00
Agency:
HHS
Principal Investigator:
Ernest V. Groman
Abstract:
DESCRIPTION (provided by applicant): The absence of a widely accepted commercially available method to measure glomerular filtration rate (GFR) in animal models and in the clinic has had profoundly negative effects on (i) developing methods and drugs for t reating kidney disease, (ii) accurately… More

Inulin immunoassay for kidney function

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$963,000.00
Agency:
HHS
Principal Investigator:
Ernest V. Groman – 508-770-1190
Abstract:
DESCRIPTION (provided by applicant): The absence of a widely accepted commercially available method to measure glomerular filtration rate (GFR) in animal models and in the clinic has had profoundly negative effects on (i) developing methods and drugs for treating kidney disease, (ii) accurately… More

Evaluate a novel product to simultaneously remove dead cells, cellular membranes,

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$147,923.00
Agency:
HHS
Principal Investigator:
Christopher P. Reinhardt – 508-770-1190
Abstract:
DESCRIPTION (provided by applicant): We hypothesize that a commercially competitive magnetic nanoparticle can be developed to eliminate debris in the preparation of cell cultures, such as stem cells. Current methods to remove unwanted material from healthycultures rely on magnetic negative selection… More

Sorted libraries of error-free long oligonucleotides

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$200,625.00
Agency:
HHS
Principal Investigator:
Ernest V. Groman – 508-770-1190
Abstract:
DESCRIPTION (provided by applicant): Iron deficiency is frequently encountered in chronic kidney disease (CKD) patients and many other populations. Current oral iron formulations are poorly tolerated. Injectable iron preparations are difficult to administer, costly and have serious adverse… More